Our Take
A real new target in bacteria, confirmed in Nature, but manikomycin is still in early development (toxicity cleared, but residency time unproven); don't mistake a promising lead for a clinical win.
Why it matters
Antibiotic resistance kills tens of thousands annually and is accelerating. A genuinely novel target—one bacteria have no evolutionary defense against—is rare enough to matter, especially if the Wright lab can prove it scales to human infection models.
Do this week
Infectious disease teams: flag manikomycin's E-site mechanism in your resistance tracking systems now, before any clinical trials begin, so you can differentiate it from existing ribosomal agents in your resistance surveillance.
McMaster researchers isolate antibiotic that exploits undefended bacterial target
A team led by Gerry Wright at McMaster University discovered manikomycin, a natural antibiotic isolated from the soil bacterium Streptomyces rimosus. The compound kills multidrug-resistant Enterobacteriaceae and other bacteria by binding to the E-site of the large ribosomal subunit, a mechanism no clinically-prescribed antibiotic currently employs (per the paper published in Nature).
The E-site is part of the bacterial ribosome's protein synthesis machinery. Manikomycin blocks the entry of the 3' end of tRNA into that site, halting the translocation step in a sequence-context-specific manner. Because no antibiotic has ever put selective pressure on this target over the history of medicine, bacteria have evolved no existing resistance mechanisms against it.
The researchers used advanced fractionation methods to isolate manikomycin from S. rimosus extracts. By filtering out abundant compounds like oxytetracycline (discovered from the same bacterium over 75 years ago), they exposed rarer molecules that had gone undetected despite decades of screening. The lab has now identified four new antibiotic candidates in just over 14 months using this approach.
Wright's team has already validated that manikomycin is non-toxic to human cells and works in controlled lab infection models. They are now optimizing the drug's residency time—how long it remains active in the body—and have synthesized 60 derivatives to identify the best candidate for advancement.
A new ribosomal target matters because existing resistance is nearly universal
Many antibiotics in clinical use today attack the ribosome, and bacteria have evolved broad, overlapping defense strategies against them. Azithromycin, tetracyclines, and other ribosomal inhibitors face widespread resistance precisely because of this evolutionary pressure.
A drug that targets a different ribosomal site avoids these established resistance mechanisms entirely. This is not a marginal improvement; it is a structural escape from the resistance landscape. If manikomycin advances to clinical use, prescribing it would not accelerate resistance to existing ribosomal antibiotics, and vice versa.
Antibiotic resistance currently causes an estimated 1.27 million deaths annually globally and is accelerating as resistance spreads. New mechanisms are no longer nice to have; they are essential. Finding a target with zero historical selective pressure is rare enough to warrant tracking.
Clinical microbiology teams should prepare now
If manikomycin enters clinical trials, it will require separate resistance surveillance and breakpoint definitions from existing ribosomal agents. Infectious disease programs and microbiology labs should begin documenting the E-site mechanism in their antibiotic resistance databases now, before any regulatory submissions arrive. This prevents confusion with other ribosomal drugs and enables rapid detection if resistance emerges during trials.
The Wright lab's next milestones are optimizing drug stability and expanding the compound's bacterial spectrum. Neither milestone has been publicly reported yet. Monitor their publication record and McMaster's clinical development announcements over the next 12-18 months.